GlassScriptPhysician profile
John D Bullock
NPI 1942217757
$4,174.63
in general payments reported to CMS, 2019-2025
33 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $451 · 2021: $580 · 2022: $633 · 2023: $907 · 2024: $722 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $884.29 | 2019-2025 | Xifaxan |
| Abbvie INC. | $494.93 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $472.82 | 2019-2024 | |
| Lilly USA, LLC | $254.69 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $185.91 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Tris Pharma INC | $174.34 | 2023-2025 | Dyanavel Xr |
| Novo Nordisk INC | $170.31 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $151.03 | 2021-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $131.14 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.06 | 2021-2022 | |
| Astellas Pharma US INC | $100.40 | 2019-2021 | |
| Amgen INC. | $96.37 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $94.37 | 2023-2025 | |
| Abbott Laboratories | $75.19 | 2023-2024 | Freestyle Libre 2, Octrode |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.07 | 2020 | |
| Novartis Pharmaceuticals Corporation | $71.56 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.03 | 2019-2024 | Ofev |
| Exact Sciences Corporation | $67.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.68 | 2019-2021 | |
| Amarin Pharma, INC. | $43.01 | 2019-2020 | |
| Ibsa Pharma INC. | $33.71 | 2022-2023 | Tirosint, Licart |
| Idorsia Pharmaceuticals US INC | $31.48 | 2022-2023 | Quviviq |
| Dexcom, INC. | $27.53 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $21.92 | 2023 | Rexulti |
| Dynavax Technologies Corporation | $19.60 | 2023 | Heplisav-B |
| Medtronic, INC. | $17.90 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.95 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.18 | 2024 | Nuzyra |
| Avanir Pharmaceuticals, INC. | $12.84 | 2022 | |
| Merck Sharp & Dohme LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bullock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.